Fig. 3. Survival rates according to histologic diagnosis

Slides:

Advertisements

Similar presentations

Childhood Cancer Gabby Kulikowski & Kellie Campbell.

Advertisements

Pediatric Neurosurgical Neuropathology

Brain tumors = leading cause of solid tumor deaths in children Low grade brain tumors = most common NO CURES CURRENT TREATMENT = TOXIC Better treatments.

Perspectives on CNS Malignancies Susan M. Staugaitis, M.D., Ph.D. Cleveland Clinic Foundation.

Tumors of the CNS can be: Primary Secondary

Pamela Simon R.N., C.P.N.P, MSN Lucile Packard Children’s Hospital

TRANSFORMING THE CHILDHOOD CANCER SURVIVOR EXPERIENCE Additional Material.

Incidence of Childhood Cancer. What is cancer ? Uncontrolled growth of cells Are these cancer cells abnormal? No, but their behaviour is.

Kara Penney Bone Cancer. Osteosarcoma Chondrosarcoma The Ewing Sarcoma Family of Tumors (ESTFs) Types of Bone Cancer.

SPINDLE CELL SARCOMA OF BONE AN ASSESSMENT OF OUTCOME

START PROGRAM: STATE-OF-THE-ART ONCOLOGY IN EUROPE RARECARENet kick-off Luxembourg – July 13, 2012 Chairperson: Dr. Lisa Licitra.

Excerpta Extraordinaire

Sarcomas Perspectives and Background. Sarcomas: Themes Sarcomas are a heterogeneous collection of diseases and families of diseases –Individual diseases/families.

INTRODUCTION TO PEDIATRIC ONCOLOGY Prof.Dr.Reha Cengizlier

In humans, billions of cells die each day Cells die in two ways: 1.Necrosis 2.Apoptosis.

Dinutuximab (ch14.18) for children with high-risk neuroblastoma

CONGENITAL NEVI. Common Malignant Neoplasms of Infancy and ChildhoodCommon Malignant Neoplasms of Infancy and Childhood 0 to 4 Years5 to 9 Years10 to.

The Histological Response to Chemotherapy as a Predictor of the Oncological Outcome of Operative Treatment of Ewing Sarcoma* by JAY S. WUNDER, GABE PAULIAN,

Finding cancerous anaplastic cells with image analysis K. Nicol, M. Plaskow, T. Barr, D. Billiter.

Brain Tumors Mark Browning, M.D. IUSME. Differential Diagnosis includes: Primary CNS tumor Most common primary sites of brain mets: – Lung – Breast.

Central Nervous System n Early n Infection (brain or meninges) n cerebrovascular- hemorrhage, infarction, thrombosis n acute encephalopathy n Late n Mineralizing.

School Nurse Update Conference November 14, 2016

Chapter 11 Cancer in Children.

PEDITRIC ONCOLOGY AN INTRODUCTION

Paediatric Oncology CWMH 2016

Malignant bone tumors Pazourek L., Ondrůšek Š..

Clinical trials in Europe

Malignancies in patients less than 6 months at MAHAK hospital

Case Rep Oncol 2017;10:462– DOI: /

تازه های پاتولوژی در تومورهای استخوان

A Rare Case of Askin’s Tumor in the 6th rib

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Fig. 3 Overall and disease-free survival of single-zone metastasis group according to the number of stations involved. No significant differences were.

Table 3. Age Distribution of Solid Malignant Tumours in Children

Midsagittal section through the brain of a patient with a brain stem tumor. Histologic findings showed the tumor to be an ependymoma. Source: Discussion.

Agency for Healthcare Research and Quality (AHRQ)

Johns Hopkins Hospital Cancer Registry

Fig year-old man with lymph-node metastasis from pelvic extraskeletal Ewing sarcoma family of tumors. A. Axial contrast-enhanced computed tomography.

Fig 3. Time trends for infant mortality rate and hazard ratio according to the deprivation quintiles. (A) Time trend for the infant mortality rate according.

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Pediatric Neurosurgical Neuropathology

Childhood Cancer Statistics, England, Annual report 2018.

Reduced tumor load in peripheral blood after treatment with G-CSF and chemotherapy in children with tumors of the Ewing sarcoma family but not neuroblastoma.

Focus on central nervous system neoplasia

Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

A–d) Comparison of Kaplan–Meier curves of a) progression-free survival (PFS) and c) overall survival (OS) in large-cell neuroendocrine carcinoma (LCNEC)

Table 2. Progression-Free Survival

Intravenous delivery of reovirus to primary and secondary brain tumors

Volume 14, Issue 4, Pages (April 2013)

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Ugo Pastorino, MD, Marc Buyse, ScD, Godehard Friedel, MD, Robert J

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Fig. 7. KIF11 informs patient prognosis, and targeting improves survival in a preclinical model. KIF11 informs patient prognosis, and targeting improves.

Volume 164, Issue 5, Pages (February 2016)

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Volume 14, Issue 4, Pages (April 2013)

Hematopoietic Stem Cell Transplantation Dr . Ghassemi A Associate professor of pediatric Hematologist Oncologist & stem cell transplantation.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Fig. 2. One case of recurrence out of 12 adult patients with totally resected ependymomas without anaplastic pathology or postoperative adjuvant treatment.

Fig. 1. Kaplan-Meier curves for PFS and OS

Percentage of peripheral blood samples that demonstrated >5-fold in vitro expansion. Percentage of peripheral blood samples that demonstrated >5-fold in.

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Fig. 2. Kaplan-Meier plots for PFS and OS of 37 patients according to histological diagnosis (A and D), the extent of tumor resection (B and E), and adjuvant.

Schematic of models of N-MYC overexpression-driven genetically engineered mouse tumor models and human tissue recombination models. Schematic of models.

H & E = hematoxylin and eosin.

Presentation transcript:

Fig. 3. Survival rates according to histologic diagnosis Fig. 3. Survival rates according to histologic diagnosis. (A) OS and PFS in patients with brain tumors. (B) PFS according to the histologic diagnosis in patients with brain tumors. (C) OS and PFS in patients with neuroblastomas. (D) PFS according to the initial risk in patients with neuroblastomas. (E) OS and PFS in patients with bone and soft tissue sarcomas. (F) PFS according to the histologic diagnosis in patients with bone and soft tissue sarcomas. (G) OS and PFS in patients with Wilms tumor. (H) OS and PFS in patients with retinoblastoma. (I) OS and PFS in patients with other tumors. (J) PFS according to the histologic diagnosis in patients with other tumors. OS = overall survival, PFS = progression-free survival, MB = medulloblastoma, HGG = high-grade glioma, ATRT = atypical teratoid/rhabdoid tumor, AE = anaplastic ependymoma, PNET = primitive neuroectodermal tumor, IC-GCT = intracranial germ cell tumor, OSA = osteosarcoma, ESFT = Ewing sarcoma family of tumor, RMS = rhabdomyosarcoma, NRSTS = non-rhabdomyomatous soft tissue sarcoma, HB = hepatoblastoma, EC-GCT = extracranial germ cell tumor. Fig. 3. Survival rates according to histologic diagnosis. (A) OS and PFS in patients with brain tumors. (B) PFS according to the histologic diagnosis in patients with brain tumors. (C) OS and PFS in patients with neuroblastomas. (D) PFS according to the initial risk in patients with neuroblastomas. (E) OS and PFS in patients with bone and soft tissue… J Korean Med Sci. 2018 Oct;33(41):e260. https://doi.org/10.3346/jkms.2018.33.e260